SHH and medulloblastoma: In recurrent, progressed, or relapsed SHH group medulloblastoma, both SHH pathway inhibitors Vismodegib and Sonidegib, targeting transmembrane protein Smoothened (SMO), were revealed with anti-tumour activities in monotherapy stratums [167], while the combination of Vismodegib and Temozolomide failed as the proportion of successes required was not reached [168].